ProKidney (PROK) Receives a Buy from Guggenheim

Guggenheim analyst Vamil Divan maintained a Buy rating on ProKidney yesterday and set a price target of $7.00. The company’s shares closed last Friday at $4.54.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
• Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.

Divan covers the Healthcare sector, focusing on stocks such as Merck & Company, Vera Therapeutics, and Amgen. According to TipRanks, Divan has an average return of 5.2% and a 51.94% success rate on recommended stocks.

Currently, the analyst consensus on ProKidney is a Hold with an average price target of $4.75, which is a 4.63% upside from current levels. In a report released on July 9, Citi also maintained a Buy rating on the stock with a $9.00 price target.

PROK market cap is currently $1.33B and has a P/E ratio of -7.53.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PROK in relation to earlier this year. Most recently, in April 2025, Carso De-C Inmobiliaria, a Major Shareholder at PROK bought 387,393.00 shares for a total of $275,049.03.